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Abstract 
The patient was a 47-year-old woman with a painful ulcer that had appeared on the right 5th 
toe two weeks before she visited our hospital. Histopathological examination showed that 
thrombi were present in small blood vessels in the dermis and pancytosis was detected in a 
blood test, suggesting polycythemia-associated ulceration of the toe. Essential 
thrombocythemia was diagnosed based on bone marrow puncture and chromosomal test 
findings. Platelet count and the ulcer were improved by oral hydroxyurea. 
 
 
Introduction 
Chronic myeloproliferative diseases include essential thrombocythemia (ET), 
polycythemia vera, chronic myelocytic leukemia and myelofibrosis, and cause 
hemorrhagic and thrombotic symptoms in many organs of the body [1]. Purpura, 
subcutaneous hemorrhage, ulcer, acral gangrene, livedo symptoms, and 
erythromelalgia can occur in the skin [2]. We encountered a patient in whom an ET-
associated ulcer of the toe was markedly improved by treatment with hydroxyurea. 
Case Report 
The patient was a 47-year-old woman in whom an ulcer had developed on the toe two weeks 
before she visited the Outpatient Clinic of our department because of pain. Polycythemia and 
hypertension had been found during a health check-up 4 years earlier, but had been left untreated. A 
purple-reddish macula accompanied by coldness and pain had appeared on the toe tip 3 years before 
and the region had repeatedly swelled for 2 years. On the first examination, a swelled, cyanotic  
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discoloration of the skin was present on the right 5th toe. An ulcer 5 mm in diameter, covered with a 
crust and accompanied by pain and numbness was noted at the toe tip (fig. 1a, b). Livedo was also 
present on the back and side of the right foot. Pulsation of the dorsal artery of the foot was good on 
both sides and intermittent claudication was absent. Histopathological examination of the ulcerated 
skin showed that the epidermis was partially defective, platelet thrombi were present in dilated small 
blood vessels in the upper to middle dermis, and inflammatory cells had infiltrated around the small 
vessels (fig. 2a). The inner wall was destroyed in some blood vessels and the structure was unclear 
with complete obstruction of the lumen (fig. 2b). No cholesterol crystals were present in the 
thrombotic region. 
Blood tests showed WBC, 19,900/μl; RBC, 628 × 104/μl; Hb, 12.9 g/dl; Ht, 43.7%; platelets, 99.4 × 
104/μl; IgG, 1,458 mg/dl; IgA, 418 mg/dl; IgM, 135 mg/dl; ferritin, 6.3 ng/ml; PR3-ANCA, negative; 
MPO-ANCA, negative; anticardiolipin antibody, negative; cryoglobulin, negative; and vitamin B12, 812 
ng/ml (normal value: 200–800). In a bone marrow test, the number of irregular-sized 
megakaryocytes with atypical nuclei was markedly increased, and the numbers of granulocyte system 
cells and erythrocyte precursors were also increased, but no myelofibrosis was noted. Philadelphia 
chromosome was negative and no other chromosomal aberrations were detected. Abdominal 
echography detected a 67 × 44-mm splenomegaly, but there were no findings suggesting infection, 
inflammatory disease, or malignant tumor. Based on these findings, ET and an accompanying skin 
ulcer were diagnosed. Administration of oral hydroxyurea at 500 mg/day was initiated and the 
patient’s platelet count was reduced to 42 × 104/μl and WBC to 9,700/μl after several months. The 
ulcer on the right 5th toe was mostly epithelialized about one month after initiation of hydroxyurea, 
and only mild livedo and pigmentation were present thereafter. 
Discussion 
ET is one of several chronic myeloproliferative diseases and has a pathology 
believed to involve hyperplasia of platelets without normal function due to abnormal 
autonomous proliferation of megakaryocyte-lineage cells in the bone marrow. ET is 
diagnosed based on a platelet count of 60 × 104/μl or higher and Ht of 40% or lower, 
normal RBCs, normal serum ferritin, a Philadelphia chromosome- or bcr/abl fusion 
gene-negative status, the exclusion of chronic myelocytic leukemia, the absence of 
marked myelofibrosis, and the exclusion of reactive thrombocythemia [1]. The 
incidence is high in persons aged 60 years and older, and the condition may be 
accompanied by deep or superficial venous thrombosis, nasal hemorrhage, intracranial 
hemorrhage, transient ischemic attack, and cerebral and myocardial infarction, 
although many cases are asymptomatic [2]. Regarding skin symptoms, purpura is most 
frequent, followed by erythromelalgia, skin ulcer, and livedo reticularis [2]. 
Skin symptoms in ET such as ulcer and gangrene are thought to develop due to an 
increased production of platelet-activating substances such as thromboxane A2 and 
prostaglandins G2 and H2. This process is induced by an increased adhesion, release and 
aggregation due to an increased platelet count, elevated sensitivity of platelets to these 
substances, decreased production of prostacyclin, which is a platelet-function inhibitor, 
and increased platelet aggregation due to decreased sensitivity of platelets to 
prostaglandins I2 and D2 [1–4]. 
To our knowledge, 25 patients with ET-associated skin ulcer/necrosis of the toe 
have been reported since 1970 [2, 5–8]. Two patients were treated with hydroxyurea 
and the ulcer markedly improved [7, 8], whereas 7 patients were treated with 
antiplatelet drugs such as aspirin, but gangrene progressed and amputation of the toe 
was required. Hydroxyurea is a metabolic antagonist that inhibits DNA synthesis, and it 
is frequently used in the treatment of myeloproliferative diseases such as chronic  
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myelocytic leukemia. Hydroxyurea has been used to treat ET in many cases since the 
1990s [1, 7, 8], with the goal of reducing the platelet count [9–11]. The patient in the 
current case was treated with hydroxyurea from the early phase, and the platelet count 
decreased and skin symptoms were improved. Hydroxyurea treatment at 500 mg/day 
is ongoing and her platelet count has stabilized at about 50–70 × 104/μl without 
recurrence of skin symptoms. It sometimes use treated for skin ulcer with antiplatelet 
drugs such as aspirin or cilostazol, cyclophosphamide for reducing the number of 
platelet [2]. 
Our case suggests that ET should be kept in mind as a possible cause of refractory 
ulcer in the crura and toes, even though the condition is rare. In such cases, early 
diagnosis and rapid treatment may prevent aggravation, and hydroxyurea is the 
treatment of choice [11–13]. 
 
 
 
 
 
 
Fig. 1. Skin symptoms. The right 5th toe was swollen and had a purple-reddish color (a). A crusted 
ulcer was present on the ventral side of the toe (b). 
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Fig. 2. Histopathological findings (hematoxylin and eosin staining). Hyperkeratosis, parakeratosis, and 
a partial defect were noted in the epidermis. Inflammatory cells infiltrated around dermal blood 
vessels (a) (×40), and the blood vessels were partially dilated and contained platelet thrombi (b) 
(×400). 
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